Laser Assisted Surgical System to Revolutionize Cardiac Bypass Surgeries
Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and
prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedur...
ver más
30/06/2023
AMT MEDICAL RESEAR...
3M€
Presupuesto del proyecto: 3M€
Líder del proyecto
AMT MEDICAL RESEARCH BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto SAFE-CAB
Duración del proyecto: 44 meses
Fecha Inicio: 2019-10-10
Fecha Fin: 2023-06-30
Líder del proyecto
AMT MEDICAL RESEARCH BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and
prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in
arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking
for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby
only used in <1-3% of all surgeries. The vision of the SAFE-CAB consortium is to make the minimally invasive CAB
surgeries available to all surgeons as a novel standard of care, thereby substantially improve patient outcomes and reduce
health care costs. The goal of the project is to bring to market a first-of-its-kind laser-assisted minimally invasive surgical
system (surgical kit containing surgical implant and laser catheter). SAFE-CAB enables minimally invasive procedure on
beating heart, without the need for arresting blood flow or complex hand suturing. With shorter recovery times, less
complications and improved survival rates in high-risk patients, the SAFE-CAB technology has a potential to replace high-risk
open-heart surgeries. Replacing only 15% of open-heart surgeries in Europe and US translates to annual
market opportunity of >€89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB
technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to
obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.